Palvella Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Palvella Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.28M, a 266.76% increase year-over-year.
- Palvella Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $956.00K, a 1326.87% increase year-over-year.
- Palvella Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $242.00K.
- Palvella Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $349.00K.
- Palvella Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $763.00K.
- Palvella Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $95.00K, a 90.72% decline from fiscal 2021.
- Palvella Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $1.02M, a 251.89% increase from fiscal 2020.
- Palvella Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $291.00K, a 47.38% decline from fiscal 2019.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.28M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $956.00K 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $763.00K 10-K · filed 2026-03-31 | |
| 2025-09-30 | $242.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $349.00K 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $67.00K 10-Q · filed 2026-08-04 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $95.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $261.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $10.00K 10-Q · filed 2023-08-10 | $827.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $85.00K 10-Q · filed 2023-05-11 | $1.09M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $166.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.02M 10-K · filed 2023-03-31 |
| 2021-09-30 | $566.00K 10-Q · filed 2022-11-04 | $878.00K derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $272.00K 10-Q · filed 2022-08-04 | $312.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $20.00K 10-Q · filed 2022-05-11 | $311.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $291.00K 10-K · filed 2022-03-02 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | |
| 2020-06-30 | $271.00K 10-Q · filed 2021-08-05 | |
| 2019-12-31 | $335.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $553.00K 10-K · filed 2021-03-31 |
| 2019-09-30 | $121.00K 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $97.00K 10-Q · filed 2020-08-10 | |
| 2018-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $986.00K 10-K · filed 2020-03-13 |
| 2018-09-30 | $144.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $13.00K 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $826.00K 10-Q · filed 2019-05-10 | |
| 2017-12-31 | $781.00K 10-K · filed 2019-03-18 | |
| 2015-12-31 | $10.00K 10-K · filed 2017-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |